ACTIVITY TITLE
Virtual Symposium and Case Simulation: Managing LDL-C to Reduce ASCVD Risk: Recent Advancements and Strategies to Optimize Patient Outcomes
ACTIVITY FORMAT
Virtual Symposium and Case Simulation
PROGRAM DESCRIPTION
In this symposium, faculty will overview the management of hypercholesterolemia to reduce the risk of adverse
atherosclerotic cardiovascular disease (ASCVD) events, including how to identify patients with statin intolerance or
with residual risk despite maximized statin therapy, as well as current management of elevated cholesterol with
statin and non-statin therapies according to the updated guidelines. In addition, the symposium will summarize the
evidence on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and emerging
cholesterol-lowering therapies. Challenges with access to newer therapies and appropriate resources to address this
issue will also be reviewed.
During the activity, case-based, patient simulation technology will be utilized to provide learners with the
opportunity to explore different decision paths and get immediate feedback on their treatment decisions, allowing
for enhanced competence in the individualization of therapy for patients at-risk for ASCVD.
Learners are also provided online access and a PDF copy of a Rapid Review Pocket Guide: Guidance on Cholesterol Management.
ESTIMATED TIME TO COMPLETE: 75 minutes
RELEASE DATE: January 17, 2020
EXPIRATION DATE: January 17, 2021
EDUCATIONAL GRANT SUPPORT
This educational activity is multi-supported by educational grants from Sanofi US and Regeneron Pharmaceuticals, The
Medicines Company, and Esperion.
INTENDED AUDIENCE
This activity is designed for US-based endocrinologists, cardiologists, lipidologists, diabetologists,
gastroenterologists, hepatologists, PAs, registered nurses, and NPs
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Identify patients with elevated LDL-C who are statin intolerant based on past medical and familial history,
adverse
effects of statins, and recommended definitions and diagnostic guidelines
- List new and emerging treatment options for ASCVD prevention or management in high-risk patients with
hypercholesterolemia
- Develop individualized treatment regimens for prevention of adverse cardiovascular events in high-risk patients
with elevated LDL-C and comorbidities based on the current ACC/AHA guidelines and evidence about the safety and
efficacy of non-statin therapies
- Employ strategies and resources designed to improve patients’ access to new treatment options for
hypercholesterolemia that may minimize risk of adverse cardiovascular events
FACULTY
Christie M. Ballantyne, MD (Chair)
- Professor of Medicine
- Chief, Section of Cardiovascular Research
- Chief, Section of Cardiology
- Department of Medicine, Baylor College of Medicine
- Director, Center for Cardiovascular Disease Prevention
- Baylor College of Medicine
- Methodist DeBakey Heart Center
- Houston, TX
Leslie Cho, MD
- Professor of Medicine
- Section Head, Preventive Cardiology and Rehabilitation
- Cleveland Clinic
- Cleveland, OH
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute
for Medicine and CMHC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American
Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category
1
Credits™ Physicians should claim only the credit commensurate with the extent of their participation in
the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours. Designated
for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
PHARMACIST ACCREDITATION STATEMENT
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125
CEUs) of the Accreditation Council for Pharmacy Education.
This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-19-1026-H01-P.
Upon completing the post-survey and the activity evaluation form, transcript information will be sent to the NABP
CPE Monitor Service within 4-6 weeks.
DIETICIAN ACCREDITATION STATEMENT
Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited
Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.5
Continuing Professional Education units (CPEUs) for completion of this activity.
This is a Level II activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in
a position to control the content of this activity to disclose any real or apparent conflict of interest (COO they
may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according
to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that
promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial
interest.
Faculty
Dr. Ballantyne discloses the following:
- Grant/Research Support: All significant. (All paid to institution, not individual): Abbott Diagnostic, Akcea,
Amgen, Esperion, Novartis, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, NIH, AHA, ADA.
- Consultant: Abbott Diagnostics, Akcea, Amarin, Amgen, AstraZeneca*, Boehringer lngelheim,
Denka Seiken, Esperion, Intercept, Janssen, Matinas BioPharma Inc, Merck*, Novartis, Novo
Nordisk, Regeneron, Roche Diagnostic, Sanofi-Synthelabo*
*Significant where noted (>$10,000); remainder modest (<$10,000).
Dr. Cho discloses the following:
Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not
indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled
indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily
represent the views of the planners. Please refer to the official prescribing information for each product for
discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and
their own professional development. The information presented in this activity is not meant to serve as a guideline
for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without evaluation of their patient's conditions
and possible contraindications and/or dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period January 17, 2020 through January 17, 2021, participants must read the learning objectives and faculty disclosures and study
the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-survey and evaluation.
Upon completing, your certificate will be made available immediately.
Media: Internet
For questions about the accreditation of this activity, please visit
www.pimed.com.
HARDWARE AND SOFTWARE REQUIREMENTS:
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not
have these browsers, you can download Chrome here,
Firefox here and
Internet Explorer
here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB
RAM.
